Alzheimer's disease (AD) is a major healthcare challenge with no curative treatment at
present. To address this challenge, we need a paradigm shift, where we focus on pre …

Currently, 3 amyloid PET tracers are approved and commercially available for clinical use.
They allow for the accurate in vivo detection of amyloid plaques, one hallmark of Alzheimer …

Three pathologic processes are characteristic of Alzheimer disease (AD): β-amyloid,
hyperphosphorylated tau, and neurodegeneration. Our understanding of AD is undergoing a …

Importance The goal of Alzheimer disease (AD) prevention together with advances in
understanding the pathophysiology of AD have led to clinical trials testing drugs in …

Introduction Disclosing amyloid status to cognitively normal individuals remains
controversial given our lack of understanding the test's clinical significance and unknown …

Background Mild cognitive impairment (MCI) has an uncertain etiology and prognosis and
may be challenging for clinicians to discuss with patients and families. Amyloid imaging may …

Background: Disclosing a diagnosis of dementia is a key process involving people with
dementia, carers, and healthcare professionals (HCPs) that can facilitate access to treatment …

Background Disclosure of amyloid positron emission tomography (PET) results to
individuals without dementia has become standard practice in secondary prevention trials …

The brain changes of Alzheimer's disease and other degenerative dementias begin long
before cognitive dysfunction develops, and in people with subtle cognitive complaints …

Background: The focus on early detection of dementia and Mild Cognitive Impairment (MCI)
diagnosis has entered the clinics' daily routine. However, there exist epistemic uncertainty …